Arena’s Lorcaserin Can Continue To Bloom In Phase III Obesity Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety monitoring board review of echocardiographic data gives firm a green light to continue with pivotal trial.
You may also be interested in...
Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial
Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.
Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial
Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.
Sanofi Withdraws Zimulti NDA For Weight Loss
Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.